Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Tailored Therapy - Increase Efficacy of Cetuximab

Share :
Published: 28 Nov 2008
Views: 13672
Rating:
Save
Erbitux and the KRAS Mutation

Tailored Therapy - Increase Efficacy of Cetuximab

Related Videos

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance...
Dr Jill Corre - IUCT Oncopole, Toulouse, France
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )
29 Oct 2024
Revolutionising myeloma treatment through immune profiling
Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA
Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )
28 Oct 2024
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Prof Joy Ho - The University of Sydney, Sydney, Australia
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )
28 Oct 2024
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...
ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )
18 Oct 2024
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced...
Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours ( Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA )
16 Oct 2024
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS...
Prof Salomon Manier - Hospital Center University De Lille, Lille, France
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )
30 Sep 2024
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Prof Philippe Moreau - University Hospital of Nantes, Nantes, France
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )
30 Sep 2024
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Dr Marina Garassino - University of Chicago, Chicago, USA
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024
Amivantamab-lazertinib continue to show benefit as a first-line standard-of...
Dr Marina Garassino - University of Chicago, Chicago, USA
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation